Literature DB >> 12788816

The antipsychotic drug chlorpromazine inhibits HERG potassium channels.

Dierk Thomas1, Kezhong Wu, Sven Kathöfer, Hugo A Katus, Wolfgang Schoels, Johann Kiehn, Christoph A Karle.   

Abstract

(1) Acquired long QT syndrome (aLQTS) is caused by prolongation of the cardiac action potential because of blockade of cardiac ion channels and delayed repolarization of the heart. Patients with aLQTS carry an increased risk for torsade de pointes arrhythmias and sudden cardiac death. Several antipsychotic drugs may cause aLQTS. Recently, cases of QTc prolongation and torsade de pointes associated with chlorpromazine treatment have been reported. Blockade of human ether-a-go-go-related gene (HERG) potassium channels, which plays a central role in arrhythmogenesis, has previously been reported to occur with chlorpromazine, but information on the mechanism of block is currently not available. We investigated the effects of chlorpromazine on cloned HERG potassium channels to determine the biophysical mechanism of block. (2) HERG channels were heterologously expressed in Xenopus laevis oocytes, and ion currents were measured using the two-microelectrode voltage-clamp technique. (3) Chlorpromazine blocked HERG potassium channels with an IC(50) value of 21.6 micro M and a Hill coefficient of 1.11. (4) Analysis of the voltage dependence of block revealed a reduction of inhibition at positive membrane potentials. (5) Inhibition of HERG channels by chlorpromazine displayed reverse frequency dependence, that is, the amount of block was lower at higher stimulation rates. No marked changes in electrophysiological parameters such as voltage dependence of activation or inactivation, or changes of the inactivation time constant were observed. (6) In conclusion, HERG channels were blocked in the closed and activated states, and unblocking occurred very slowly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12788816      PMCID: PMC1573882          DOI: 10.1038/sj.bjp.0705283

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  The heart of psychotropic drug therapy.

Authors:  H Tie; B D Walker; S M Valenzuela; S N Breit; T J Campbell
Journal:  Lancet       Date:  2000-05-20       Impact factor: 79.321

Review 3.  Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.

Authors:  J D Hoehns; R H Stanford; D R Geraets; K S Skelly; H C Lee; B L Gaul
Journal:  Pharmacotherapy       Date:  2001-07       Impact factor: 4.705

4.  High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872.

Authors:  D Thomas; G Wendt-Nordahl; K Röckl; E Ficker; A M Brown; J Kiehn
Journal:  J Pharmacol Exp Ther       Date:  2001-05       Impact factor: 4.030

5.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

6.  Antiarrhythmic drug carvedilol inhibits HERG potassium channels.

Authors:  C A Karle; V A Kreye; D Thomas; K Röckl; S Kathöfer; W Zhang; J Kiehn
Journal:  Cardiovasc Res       Date:  2001-02-01       Impact factor: 10.787

Review 7.  Long QT syndromes and torsade de pointes.

Authors:  S Viskin
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

8.  Novel characteristics of a misprocessed mutant HERG channel linked to hereditary long QT syndrome.

Authors:  E Ficker; D Thomas; P C Viswanathan; A T Dennis; S G Priori; C Napolitano; M Memmi; B A Wible; E S Kaufman; S Iyengar; P J Schwartz; Y Rudy; A M Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-10       Impact factor: 4.733

9.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG.

Authors:  J Kang; L Wang; X L Chen; D J Triggle; D Rampe
Journal:  Mol Pharmacol       Date:  2001-01       Impact factor: 4.436

10.  Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

Authors:  J S Mitcheson; J Chen; M C Sanguinetti
Journal:  J Gen Physiol       Date:  2000-03       Impact factor: 4.086

View more
  13 in total

Review 1.  Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.

Authors:  Deborah L Wolbrette
Journal:  Curr Cardiol Rep       Date:  2004-09       Impact factor: 2.931

2.  Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine.

Authors:  Sabrina Obers; Ingo Staudacher; Eckhard Ficker; Adrienne Dennis; Ronald Koschny; Hande Erdal; Ramona Bloehs; Jana Kisselbach; Christoph A Karle; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-13       Impact factor: 3.000

3.  Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.

Authors:  Dierk Thomas; Sven Kathofer; Wei Zhang; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

4.  Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.

Authors:  Dierk Thomas; Bettina C Hammerling; Kezhong Wu; Anna-Britt Wimmer; Eckhard K Ficker; Glenn E Kirsch; Mary C Kochan; Barbara A Wible; Eberhard P Scholz; Edgar Zitron; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

5.  Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.

Authors:  Dagmar Kubitza; Wolfgang Mueck; Michael Becka
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

6.  Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.

Authors:  Dierk Thomas; Anna-Britt Wimmer; Kezhong Wu; Bettina C Hammerling; Eckhard K Ficker; Yuri A Kuryshev; Johann Kiehn; Hugo A Katus; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-20       Impact factor: 3.000

7.  Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.

Authors:  Eberhard P Scholz; Franziska M Konrad; Daniel L Weiss; Edgar Zitron; Claudia Kiesecker; Ramona Bloehs; Martin Kulzer; Dierk Thomas; Sven Kathöfer; Alexander Bauer; Martin H Maurer; Gunnar Seemann; Hugo A Katus; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-27       Impact factor: 3.000

Review 8.  Ether-a-go-go-related gene potassium channels: what's all the buzz about?

Authors:  Paul D Shepard; Carmen C Canavier; Edwin S Levitan
Journal:  Schizophr Bull       Date:  2007-09-28       Impact factor: 9.306

9.  Stereoselective Inhibition of the hERG1 Potassium Channel.

Authors:  Liliana Sintra Grilo; Pierre-Alain Carrupt; Hugues Abriel
Journal:  Front Pharmacol       Date:  2010-11-22       Impact factor: 5.810

10.  Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment.

Authors:  Pareesa Kamgar-Dayhoff; Tinatin I Brelidze
Journal:  Oncotarget       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.